Results 81 to 90 of about 18,836 (198)

Long‐Term Use of Rezafungin: A Case Report and Insights Into Real‐World Access

open access: yes
Transplant Infectious Disease, EarlyView.
Jian Mei Li   +2 more
wiley   +1 more source

Posaconazole Induced Diffuse Lentigines: A Case Report [PDF]

open access: yes, 2018
Objective: To report a case of posaconazole induced diffuse lentigines. Case presentation: A 57-year-old Thai male with acute promyelocytic leukemia who received chemotherapy and antifungal drug prophylaxis then appeared abruptly generalized multiple ...
Kittipoom Chinhiran   +3 more
core   +1 more source

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection

open access: yesBiomedicines, 2017
Mortality and morbidity due to invasive fungal infections have increased over the years. Posaconazole is a second-generation triazole agent with an extended spectrum of activity, which shows a high interindividual variability in its plasma levels ...
Sarah Allegra   +9 more
doaj   +1 more source

Real‐World Use of Rezafungin for the Treatment of Challenging Aspergillus Infections

open access: yesMycoses, Volume 69, Issue 11, November 2026.
ABSTRACT Background Aspergillus infections can pose significant treatment challenges, due in part to increasing triazole resistance. Clinical insight is needed to understand the potential for rezafungin, a next‐generation echinocandin with once‐weekly dosing, to address some limitations of current treatments for Aspergillus infections.
Neil Stone   +9 more
wiley   +1 more source

Role of posaconazole in the treatment of oropharyngeal candidiasis

open access: yes, 2010
Voichita Ianas1, Kathryn R Matthias2, Stephen A Klotz11Section of Infectious Diseases and Department of Medicine, 2School of Pharmacy, University of Arizona, Tucson, Arizona, USAAbstract: Posaconazole is the newest azole antifungal approved by the US ...
Voichita Ianas   +2 more
core  

Posaconazole inhibits dengue virus replication by targeting oxysterol-binding protein

open access: yes, 2018
Dengue virus (DENV) is associated with an estimated 390 million infections per year, occurring across approximately 100 countries in tropical and sub-tropical regions.
Overheul, Gijs J   +24 more
core   +1 more source

Design Considerations for Polymer–Deep Eutectic Solvent Hybrid Systems for Transdermal Drug Delivery

open access: yesJournal of Applied Polymer Science, Volume 143, Issue 40, October 20, 2026.
Deep eutectic solvents (DESs) act as tunable, green excipients that modulate polymer structure–property relationships to enhance drug solubility, skin permeation, stability, and controlled release. Through hydrogen‐bond interactions, DES–polymer hybrid systems enable improved transdermal performance, offering a rational, design‐driven platform for ...
Madhavi Kailas Kapale   +3 more
wiley   +1 more source

Match-making for posaconazole through systems thinking [PDF]

open access: yes, 2014
Currently available drugs for Chagas' disease are limited by toxicity and low efficacy in the chronic stage. Posaconazole, the most advanced new anti-chagasic drug candidate, did not fully confirm its initial potential in a Phase II clinical trial for ...
Fügi, Matthias A.   +11 more
core   +1 more source

Posaconazole for lobomycosis

open access: yesThe Brazilian Journal of Infectious Diseases, 2021
Alessandro C. Pasqualotto   +4 more
openaire   +3 more sources

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis

open access: yes, 2019
Pannee Leelawattanachai,1,2 Preecha Montakantikul,1 Wichit Nosoongnoen,1 Methee Chayakulkeeree31Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; 2Department of Pharmacy, Faculty of ...
Chayakulkeeree M   +3 more
core  

Home - About - Disclaimer - Privacy